- Home
- ENVB vs YCBD Comparison
ENVB vs YCBD Comparison
Compare ENVB & YCBD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENVB
- YCBD
- Stock Information
- Founded
- ENVB 1994
- YCBD 2015
- Country
- ENVB United States
- YCBD United States
- Employees
- ENVB N/A
- YCBD N/A
- Industry
- ENVB Biotechnology: Pharmaceutical Preparations
- YCBD Biotechnology: Pharmaceutical Preparations
- Sector
- ENVB Health Care
- YCBD Health Care
- Exchange
- ENVB Nasdaq
- YCBD Nasdaq
- Market Cap
- ENVB 3.3M
- YCBD 3.2M
- IPO Year
- ENVB N/A
- YCBD N/A
- Fundamental
- Price
- ENVB $1.36
- YCBD $0.45
- Analyst Decision
- ENVB
- YCBD
- Analyst Count
- ENVB 0
- YCBD 0
- Target Price
- ENVB N/A
- YCBD N/A
- AVG Volume (30 Days)
- ENVB 564.4K
- YCBD 2.0M
- Earning Date
- ENVB 03-25-2025
- YCBD 02-13-2025
- Dividend Yield
- ENVB N/A
- YCBD N/A
- EPS Growth
- ENVB N/A
- YCBD N/A
- EPS
- ENVB N/A
- YCBD N/A
- Revenue
- ENVB N/A
- YCBD $19,220,238.00
- Revenue This Year
- ENVB N/A
- YCBD $13.00
- Revenue Next Year
- ENVB N/A
- YCBD $10.00
- P/E Ratio
- ENVB N/A
- YCBD N/A
- Revenue Growth
- ENVB N/A
- YCBD N/A
- 52 Week Low
- ENVB $1.26
- YCBD $0.31
- 52 Week High
- ENVB $657.00
- YCBD $1.34
- Technical
- Relative Strength Index (RSI)
- ENVB 16.91
- YCBD 42.04
- Support Level
- ENVB $1.26
- YCBD $0.42
- Resistance Level
- ENVB $1.70
- YCBD $0.69
- Average True Range (ATR)
- ENVB 0.17
- YCBD 0.06
- MACD
- ENVB 2.34
- YCBD -0.02
- Stochastic Oscillator
- ENVB 12.20
- YCBD 10.98
About ENVB Enveric Biosciences Inc.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders. The company's lead program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. Enveric is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, being studied as a treatment of psychiatric disorders.
About YCBD cbdMD Inc.
cbdMD Inc is a United States based company. It owns and operates the consumer hemp-based cannabidiol (CBD) brand, cbdMD, Paw CBD as well as ATRx Labs brand of functional mushrooms. The company's product categories include CBD tinctures, CBD gummies, CBD topicals, CBD capsules, CBD oils, and CBD pet products. The firm distributes its products through an e-commerce website, wholesalers, and a variety of brick-and-mortar retailers.